BioSpace News Archive

BioMidwest

MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

MBX Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for MBX 1416, the company’s long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist, being developed for the treatment of post-bariatric hypoglycemia (PBH).

August 7, 2023
·
3 min read
Business

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

Voyager Therapeutics, Inc. today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO).

August 7, 2023
·
5 min read
Business

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

PDS Biotechnology Corporation today announced that the Company will release financial results for the second quarter of 2023 on Monday, August 14, 2023, before the market opens.

August 7, 2023
·
2 min read
Business

Exagen Inc. Reports Strong Second Quarter 2023 Results

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023.

August 7, 2023
·
7 min read
FDA

Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System

Trinity Biotech has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Premier Resolution System, an automated analyzer for the accurate & precise quantification of hemoglobins F and A2, and the detection of >200 hemoglobin variants.

August 7, 2023
·
4 min read
Drug Development

Halia Therapeutics Announces Completion of Enrollment for Phase I Clinical Trial of HT-6184 for Chronic Inflammation

Halia Therapeutics today announced the completion of enrollment in its Phase I study ( NCT05447546 ).

August 7, 2023
·
3 min read